226 related articles for article (PubMed ID: 28214872)
1. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.
Xu Y; Chen L; Xu B; Xiong Y; Yang M; Rui X; Shi L; Wu C; Jiang J; Lu B
Cell Physiol Biochem; 2017; 41(2):475-483. PubMed ID: 28214872
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
Bachmayr-Heyda A; Aust S; Heinze G; Polterauer S; Grimm C; Braicu EI; Sehouli J; Lambrechts S; Vergote I; Mahner S; Pils D; Schuster E; Thalhammer T; Horvat R; Denkert C; Zeillinger R; Castillo-Tong DC
BMC Cancer; 2013 Sep; 13():422. PubMed ID: 24044611
[TBL] [Abstract][Full Text] [Related]
3. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer.
Chen LJ; Zheng X; Shen YP; Zhu YB; Li Q; Chen J; Xia R; Zhou SM; Wu CP; Zhang XG; Lu BF; Jiang JT
Cancer Immunol Immunother; 2013 Mar; 62(3):553-61. PubMed ID: 23090288
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
6. T-bet
Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
8. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis.
Le Page C; Marineau A; Bonza PK; Rahimi K; Cyr L; Labouba I; Madore J; Delvoye N; Mes-Masson AM; Provencher DM; Cailhier JF
PLoS One; 2012; 7(6):e38541. PubMed ID: 22685580
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
Leffers N; Gooden MJ; de Jong RA; Hoogeboom BN; ten Hoor KA; Hollema H; Boezen HM; van der Zee AG; Daemen T; Nijman HW
Cancer Immunol Immunother; 2009 Mar; 58(3):449-59. PubMed ID: 18791714
[TBL] [Abstract][Full Text] [Related]
10. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
Yildirim N; Akman L; Acar K; Demir S; Ozkan S; Alan N; Zekioglu O; Terek MC; Ozdemir N; Ozsaran A
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():55-61. PubMed ID: 28601728
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
[TBL] [Abstract][Full Text] [Related]
12. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer.
Zhang Z; Huang J; Zhang C; Yang H; Qiu H; Li J; Liu Y; Qin L; Wang L; Hao S; Zhang F; Wang X; Shan B
Cancer Gene Ther; 2015 Mar; 22(4):198-206. PubMed ID: 25721210
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
Peng DX; Luo M; Qiu LW; He YL; Wang XF
Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
[TBL] [Abstract][Full Text] [Related]
14. T cell density and location can influence the prognosis of ovarian cancer.
Al-Attar A; Shehata M; Durrant L; Moseley P; Deen S; Chan S
Pathol Oncol Res; 2010 Sep; 16(3):361-70. PubMed ID: 20024633
[TBL] [Abstract][Full Text] [Related]
15. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
[TBL] [Abstract][Full Text] [Related]
17. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
18. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
Bu M; Shen Y; Seeger WL; An S; Qi R; Sanderson JA; Cai Y
Tumour Biol; 2016 Mar; 37(3):3949-56. PubMed ID: 26482613
[TBL] [Abstract][Full Text] [Related]
19. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
James FR; Jiminez-Linan M; Alsop J; Mack M; Song H; Brenton JD; Pharoah PDP; Ali HR
BMC Cancer; 2017 Sep; 17(1):657. PubMed ID: 28931370
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
